Julie G. Allickson, Ph.D., is the Michael S. and Mary Sue Shannon Family Director for Regenerative Medicine and the Otto Bremer Trust Director of Biomanufacturing and Product Development in the Mayo Clinic Center for Regenerative Biotherapeutics.
In this role, Dr. Allickson leads the next phase of development of the Center for Regenerative Biotherapeutics as it delivers on innovations that cure, connect and transform patient care in alignment with Mayo Clinic's 2030 vision.
Dr. Allickson joined Mayo Clinic from Wake Forest Institute for Regenerative Medicine at Wake Forest School of Medicine, where she was the chief manufacturing development center officer.
An experienced scientist with regulatory expertise, she has more than 25 years of experience in clinical translation of cellular therapies and regenerative medicine products, including business management, board directorship experience, and knowledge of regulatory affairs, strategic planning, project management and team building.
- Address the unmet needs of patients, particularly those who need top-of-the-pyramid care.
- Execute a new biomanufacturing strategy to bring novel cures to the practice and deliver next-generation biotherapeutics that enhance Mayo Clinic's reputation as a global leader in regenerative medicine.
- Engage with industry to commercialize new discoveries made at Mayo Clinic.
- Focus on the translation of regenerative medicine products, including cell therapy, tissue engineering, biomaterials and devices. This process begins at proof of concept, when early discussions with regulators and clinicians are critical in moving the technology from the bench to the bedside.
- Design, develop and facilitate alliances with academia, industry and government agencies to bring regenerative medicine to patients worldwide, including those in underserved communities.
- Promote collaboration with Mayo Clinic's Department of Laboratory Medicine and Pathology, Mayo Clinic Center for Individualized Medicine, and Mayo Clinic Comprehensive Cancer Center, focusing on developing and delivering regenerative biotherapies.
- Introduce new regenerative therapeutics into the practice and establish Mayo Clinic as a category of one in regenerative medicine for rare and complex conditions.
Significance to patient care
Dr. Allickson directs the enterprisewide biomanufacturing strategy that aspires to introduce new regenerative therapeutics into the practice, providing regenerative medicine therapies for rare and complex conditions — particularly for patients who need specialized, best-in-class care.
By designing, developing and facilitating alliances for regenerative medicine therapies, Dr. Allickson helps make new treatments available to patients worldwide, including those in underserved communities.
- Vice chair, Cord Blood Association Quality Standards Committee, 2017-present
- Scientific advisor, Regenerative Outcomes Foundation, 2016-present
- Editorial board, CellR4, 2015-present
- Technical advisory board, Tissue Engineered Products, International Council for Commonality in Blood Banking Automation, 2015-present
- International Society for Cell and Gene Therapy
- Commercialization Committee, 2014-present
- Founding member, 1992-present
- American Association of Blood Banks
- Member, 1989-present
- Board of directors, 2016-2020
- Executive committee, Wake Forest Institute for Regenerative Medicine, 2014-2021